Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on BioVie and maintained a price target of $11.
August 22, 2023 | 1:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on BioVie, maintaining a price target of $11.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for BioVie. The maintained price target of $11 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100